Activation of receptor for advanced glycation end products - A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

被引:640
作者
Schmidt, AM
Yan, SD
Wautier, JL
Stern, D
机构
[1] Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Dept Cellular Biophys, New York, NY 10032 USA
[6] UFR Lariboisiere St Louis, Lab Biol Vasc & Cellulaire, Paris, France
关键词
glycoxidation; diabetes; nuclear factor-kappa B; inflammation; amyloid;
D O I
10.1161/01.RES.84.5.489
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 89 条
  • [71] ADVANCED MAILLARD REACTION END-PRODUCTS ARE ASSOCIATED WITH ALZHEIMER-DISEASE PATHOLOGY
    SMITH, MA
    TANEDA, S
    RICHEY, PL
    MIYATA, S
    YAN, SD
    STERN, D
    SAYRE, LM
    MONNIER, VM
    PERRY, G
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) : 5710 - 5714
  • [72] URINARY ALBUMIN EXCRETION, CARDIOVASCULAR-DISEASE, AND ENDOTHELIAL DYSFUNCTION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    STEHOUWER, CDA
    NAUTA, JJP
    ZELDENRUST, GC
    HACKENG, WHL
    DONKER, AJM
    DENOTTOLANDER, GJH
    [J]. LANCET, 1992, 340 (8815) : 319 - 323
  • [73] 3 GENES IN THE HUMAN MHC CLASS-III REGION NEAR THE JUNCTION WITH THE CLASS-II - GENE FOR RECEPTOR OF ADVANCED GLYCOSYLATION END-PRODUCTS, PBX2 HOMEOBOX GENE AND A NOTCH HOMOLOG, HUMAN COUNTERPART OF MOUSE MAMMARY-TUMOR GENE INT-3
    SUGAYA, K
    FUKAGAWA, T
    MATSUMOTO, K
    MITA, K
    TAKAHASHI, E
    ANDO, A
    INOKO, H
    IKEMURA, T
    [J]. GENOMICS, 1994, 23 (02) : 408 - 419
  • [74] A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection
    Suzuki, H
    Kurihara, Y
    Takeya, M
    Kamada, N
    Kataoka, M
    Jishage, K
    Ueda, O
    Sakaguchi, H
    Higashi, T
    Suzuki, T
    Takashima, Y
    Kawabe, Y
    Cynshi, O
    Wada, Y
    Honda, M
    Kurihara, H
    Aburatani, H
    Doi, T
    Matsumoto, A
    Azuma, S
    Noda, T
    Toyoda, Y
    Itakura, H
    Yazaki, Y
    Horiuchi, S
    Takahashi, K
    Kruijt, JK
    vanBerkel, TJC
    Steinbrecher, UP
    Ishibashi, S
    Maeda, N
    Gordon, S
    Kodama, T
    [J]. NATURE, 1997, 386 (6622) : 292 - 296
  • [75] Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain
    Takeda, A
    Yasuda, T
    Miyata, T
    Mizuno, K
    Li, M
    Yoneyama, S
    Horie, K
    Maeda, K
    Sobue, G
    [J]. NEUROSCIENCE LETTERS, 1996, 221 (01) : 17 - 20
  • [76] Taki Hideki, 1997, Journal of the Japan Diabetes Society, V40, P99
  • [77] 5-YEAR INCIDENCE OF ATHEROSCLEROTIC VASCULAR-DISEASE IN RELATION TO GENERAL RISK-FACTORS, INSULIN LEVEL, AND ABNORMALITIES IN LIPOPROTEIN COMPOSITION IN NON-INSULIN-DEPENDENT DIABETIC AND NONDIABETIC SUBJECTS
    UUSITUPA, MIJ
    NISKANEN, LK
    SIITONEN, O
    VOUTILAINEN, E
    PYORALA, K
    [J]. CIRCULATION, 1990, 82 (01) : 27 - 36
  • [78] VIBERTI G, 1983, AM J MED, V146, P688
  • [79] ADVANCED GLYCATION END-PRODUCTS CONTRIBUTE TO AMYLOIDOSIS IN ALZHEIMER-DISEASE
    VITEK, MP
    BHATTACHARYA, K
    GLENDENING, JM
    STOPA, E
    VLASSARA, H
    BUCALA, R
    MANOGUE, K
    CERAMI, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4766 - 4770
  • [80] IDENTIFICATION OF GALECTIN-3 AS A HIGH-AFFINITY BINDING-PROTEIN FOR ADVANCED GLYCATION END-PRODUCTS (AGE) - A NEW MEMBER OF THE AGE-RECEPTOR COMPLEX
    VLASSARA, H
    LI, YM
    IMANI, F
    WOJCIECHOWICZ, D
    YANG, Z
    LIU, FT
    CERAMI, A
    [J]. MOLECULAR MEDICINE, 1995, 1 (06) : 634 - 646